Paxil: The Truth Revealed by Alison Bass
As I have mentioned in an earlier post, since coming over to the plaintiff's side, I have handled several cases involving children and adolescents prescribed SSRI antidepressants who shortly thereafter, committed suicide. I learned from these cases how the drug companies promoted these drugs to pediatricians telling them how safe they were and suggesting they be given to kids who are just having a "tough time of it" as they go through the challenges of adolescents. In turn, pediatricians handed these drugs out like candy to unsuspecting parents, explaining how it would help take the edge off for their child and was very safe. I also learned how the drug companies doctored their studies so indications of suicidal thoughts by those involved in the study were hidden and just kicked out of the study for "non-compliance issues".

Now, as reported at Pharmalot, one of my favorite websites for information on the drug industry, Alison Bass, a reporter at the Boston Globe in the 1990s, has written a book to be published this week entitled "Side Effects: A Prosecutor, A Whistleblower and A Best-Selling Antidepressant on Trial". Pharmalot's post includes a great interview with Ms. Bass. Among other things, when asked about what she learned from investigating the suicide issue and the SSRI Paxil, she had these thoughts:
"There has to be full disclosure of clinical trial data. And doctors have to acknowledge when they have conflicts of interest. Major academic centers should have requirements that doctors aren’t allowed to earn more than ‘X’ amount from a drug company. As I wrote in my blog recently, Marty Keller, the principal Paxil investigator at Brown University for the 329 study, acknowledged receiving consulting fees from Glaxo, but never reported them on his tax return. Researchers who are getting lucrative personal payments should be prohibited from studying these drugs if they’re making more than whatever minimum is established by the institution. But you know, these studies are a great source of income for these institutions."
As Ms. Bass explains and what is most concerning is that this is not a problem with just Paxil and SSRI's. It is a much deeper and more widespread issue across the pharmaceutical industry as a whole, as we have continued to see with drugs such as Vioxx, Vytorin and Trasylol. We as consumers, must continue to press our legislators and these corporations to incorporate protections and practices which will allow the consuming public to feel that all that is known about the drug at issue, including all potential safety issues, have been disclosed


